ClinicalTrials.gg
CompletedNCT01934166Updated Nov 8, 2016

Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects

A Phase 1 interventional study of Nalmefene 18 mg in Renal Impairment, sponsored by H. Lundbeck A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-08.

Sponsored by H. Lundbeck A/S · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Renal Insufficiency with a site in Germany — 12 open to participants now, 16 under way, 2 of them phase 3. Renal Insufficiency · Germany.

Enrollment
76th of 113
32 · median 42
Started
2013
with 5 others
Phase 1
54 of 139
1 open now
Registered
51st of 139
by date
Lead sponsor
3 of 139
H. Lundbeck A/S

Among the 139 studies in Renal Insufficiency with a site in Germany, this one is the 76th largest by enrollment of the 113 interventional ones that give a count, is one of 6 that started in 2013, is one of 54 in phase 1, and was the 51st registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

12 of the 139 studies in Renal Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Renal Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

To investigate if renal impairment will have an impact on the pharmacokinetics of nalmefene

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy young subjects and subjects with renal impairment with a (GFR) of 50-80 ml/min/1.73m2, 30-\<50 ml/min/1.73m2, \<30 ml/min/1.73m2 will be included in the study.
  • The subjects must have a between 19 and 32 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • The subject has a history of renal transplant or is undergoing dialyse treatment.
  • The subject is, in the opinion of the investigator, unlikely to comply with the protocol or is unsuitable for any reason.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Nalmefene 18 mg

    18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride

    Drug: Nalmefene 18 mg

Interventions

06

What researchers measure

Primary outcomes

  1. For nalmefene and the metabolite nalmefene 3-O-glucuronide: area under the plasma concentration-time curve from zero to infinity (AUC0-inf)

    Time frame: Up to 120 hours post-dose

  2. For nalmefene and the metabolite nalmefene 3-O-glucuronide: area under the plasma concentration-time curve from zero to time t (t being the time for last quantifiable concentration) (AUC0-t)

    Time frame: Up to 120 hours post-dose

  3. For nalmefene and the metabolite nalmefene 3-O-glucuronide: maximum observed concentration (Cmax)

    Time frame: Up to 120 hours post-dose

  4. For nalmefene and the metabolite nalmefene 3-O-glucuronide: nominal time corresponding to the occurrence of Cmax (tmax)

    Time frame: Up to 120 hours post-dose

  5. For nalmefene and the metabolite nalmefene 3-O-glucuronide: apparent elimination half life in plasma (t½)

    Time frame: Up to 120 hours post-dose

  6. For nalmefene and the metabolite nalmefene 3-O-glucuronide: renal Clearance (CLR)

    Time frame: Up to 120 hours post-dose

  7. For nalmefene: oral clearance for nalmefene defined as dose/AUC0-inf (CL/F)

    Time frame: Up to 120 hours post-dose

  8. For nalmefene: apparent volume of distribution for nalmefene (Vz /F)

    Time frame: Up to 120 hours post-dose

  9. For the metabolite nalmefene 3-O-glucuronide: metabolic ratio (MR) defined as AUC0-inf,metabolite/AUC0-inf,parent

    Time frame: Up to 120 hours post-dose

Secondary outcomes

  1. Safety and tolerability

    Number of adverse events

    Time frame: Up to 10 days

07

Study locations

1 site
  • DE801
    Munich, 81241, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013 and a primary completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2013
First posted
Sep 4, 2013
Start
Jul 2013
Primary completionActual
Aug 2014
Last update
Nov 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01934166
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Sep 4, 2013
Start date
Jul 2013
Primary completion
Aug 2014
Last update
Nov 8, 2016

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalmefene

Start the discussion